Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$7.80 USD
-0.10 (-1.27%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $7.81 +0.01 (0.13%) 6:24 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
RAPT 7.80 -0.10(-1.27%)
Will RAPT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RAPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RAPT
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
RAPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates
How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48%
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Other News for RAPT
Hold Rating on RAPT Therapeutics Amid Promising Data and Regulatory Uncertainties
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Biotech Alert: Searches spiking for these stocks today
Maintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertainty
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients